{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:10Z","timestamp":1787027050210,"version":"build-2736575974"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma, highlighting their efficacy and toxicity as well as discussing future directions.<\/jats:p>","DOI":"10.3389\/fonc.2024.1394057","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:40:45Z","timestamp":1719794445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas"],"prefix":"10.3389","volume":"14","author":[{"given":"Bei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Korsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \"real world\" study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"B10","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol. The"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3196_LBA3","article-title":"(Liso-cel) in r\/r mcl: primary analysis results from the mcl cohort of the single-arm, multicenter, seamless design transcend nhl 001 study","volume":"41","author":"Wang","year":"2023","journal-title":"Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B28","first-page":"4471","article-title":"JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL","volume":"130","author":"Ramsborg","year":"2017","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid mantle cell lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e19583","article-title":"Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium","volume":"40","author":"Jain","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102503","article-title":"CAR T-cells for CNS lymphoma: driving into new terrain","volume":"13","author":"Karschnia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","volume":"5","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2023","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008031","article-title":"CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse","volume":"7","author":"Vu","year":"2023","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00277-023-05408-x","article-title":"Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement","volume":"102","author":"Caillet","year":"2023","journal-title":"Ann Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26233","article-title":"Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis","volume":"96","author":"Khurana","year":"2021","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.037","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (Pt) with R\/R MCL: subgroup analyses in pts with high-risk disease features from the MCL cohort of the TRANSCEND NHL 001","volume":"30","author":"Palomba","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American society for blood and marrow transplantation pharmacy special interest group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B53","article-title":"Etanercept in the treatment of macrophage activation syndrome","volume":"28","author":"Prahalad","year":"2001","journal-title":"J Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000338179","article-title":"Critical imbalance of TNF-alpha and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment","volume":"128","author":"Flammiger","year":"2012","journal-title":"Acta Haematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier","volume":"55","author":"Gutierrez","year":"1994","journal-title":"J Neuroimmunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study","volume":"31","author":"Galea","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic Malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplantat"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell Malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Therapy Off Publ Am Soc Transplant Cell Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18868","article-title":"Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer","volume":"202","author":"McCulloch","year":"2023","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02857","article-title":"Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells","volume":"10","author":"Lai","year":"2019","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic Malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","volume":"56","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1894158","article-title":"Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed\/refractory mantle cell lymphoma in the United States","volume":"24","author":"Simons","year":"2021","journal-title":"J Med Econ"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030164","article-title":"Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada","volume":"29","author":"Ball","year":"2022","journal-title":"Curr Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2079317","article-title":"Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed\/refractory mantle cell lymphoma post BTKi in England","volume":"25","author":"Petersohn","year":"2022","journal-title":"J Med Econ"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2215888","article-title":"Cost-Effectiveness of brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Marchetti","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.7326\/M22-2276","article-title":"Second-line chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma : A cost-effectiveness analysis","volume":"176","author":"Kelkar","year":"2023","journal-title":"Ann Intern Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e2245956","DOI":"10.1001\/jamanetworkopen.2022.45956","article-title":"Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"5","author":"Choe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016747","article-title":"Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati","year":"2022","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17197","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","author":"Jain","year":"2021","journal-title":"Br J Haematol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Canc"},{"key":"B93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Canc"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801327","article-title":"Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","article-title":"The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139468","article-title":"VLS-101, a ROR1-targeting antibody-drug conjugate, demonstrates a predictable safety profile and clinical efficacy in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e034629","DOI":"10.1136\/bmjopen-2019-034629","article-title":"Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)","volume":"10","author":"George","year":"2020","journal-title":"BMJ Open"},{"key":"B100","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by Malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/cas9: A powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1394057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:40:53Z","timestamp":1719794453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1394057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":102,"alternative-id":["10.3389\/fonc.2024.1394057"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1394057","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"1394057"}}